Goutweed (Aegopodium podagraria L.) biological activity and the possibilities of its use for the correction of the lipid metabolism disorders

O. Tovchiga, O. Koyro, S. Stepanova, S. Shtrygol’, V. Evlash, V. Gorban’,, T. Yudkevich


The article summarizes data concerning the biological activity of the promising herbal raw material: aerial part of goutweed (Aegopodium podagraria L., Apiaceae). This plant since time immemorial has been used as vegetable and fodder plant as well as in folk medicine including the treatment of the metabolic disorders. Nowadays the interest in this plant increases. The technology of obtaining the extract and the tincture from goutweed aerial part is described, the chemical composition of these preparations is elucidated. Pharmacological effects of the preparations obtained from goutweed are characterized with the special emphasis on the possibilities of the lipid metabolism disorders correction and prevention. The presented experimental results substantiate the efficacy of goutweed extract and the tincture under the conditions of alimentary lipemia together with their safety in the intact animals. Thus, the hypolipidemic activity of goutweed extract (1 g/kg intragastrically) and goutweed tincture (1 cm3/kg intragastrically) was shown in the test with olive oil loading in rats. The extract appeared to be able to decrease significantly the level of triglycerides in blood plasma, while the tincture reduced the content of plasma total lipids. In the intact rats, the extract at doses of 100 mg/kg and 1 g/kg as well as the tincture at doses of 1 and 5 cm3/kg did not influence on the values of the lipid metabolism after 12 days of administration. Total and HDL cholesterol as well as atherogenic index and plasma total lipids level remained unchanged. In contast to the data previously obtained on the models of hyperuricemia, in the intact rats there were no changes in plasma uric acid concentration (which was determined proceeding from the role of the purine metabolism disorders in metabolic syndrome pathogenesis). Thus, goutweed preparations are characterized with the regulatory mode of action and sufficient level of safety. The development of drugs as well as functional foods containing goutweed herbal raw material is promising.

Ключові слова

goutweed (Aegopodium podagraria L.);herbal raw material; herbal drugs; lipid metabolism; functional foods

Повний текст:



Adams M, Berset C, Kessler M, Hamburger M. Medicinal herbs for the treatment of rheumatic disorders – a survey of European herbals from the 16th and 17th century. J. Ethnopharmacol. 2009; 121: 343–359. doi: 10.1016/j.jep.2008.11.010.

Łuczaj Ł. Changes in the utilization of wild green vegetables in Poland since the 19th century: A comparison of four ethnobotanical surveys. J. Ethnopharm. 2010; 128: 395–400. doi: 10.1016/j.jep.2010.01.038.

Duke JA, Bogenschutz-Godwin MJ, duCellier P, Duke PA. Handbook of Medicinal Herbs. 2nd Ed. Boca Raton: CRC Press; 2002.

Budancev AL, Lesiovskaja EE. Dikorastushhie poleznye rastenija Rossii. SPb.: SPChPhA, 2001.

Hrodzyns'kyy AM. editor. Likars'ki roslyny: Entsykloped. dovid. Kyiv.: Holov. red. URE; 1990.

Kunstman P, Wojcińska M, Popławska P, Kunstman P. Podagrycznik pospolity (Aegopodium podagraria L.). Postępy Fitoterapii. 2012;4:244–249.

Tovchiga OV, Shtrygol’ SYu, Stepanova SI. Agent possessing uricozuric activity. Ukraine patent 76891, Sept 15, 2006.

Tovchiga OV, Shtrygol’ SYu, Stepanova SI. Use of 20% tincture of bishop'sweed with 70% ethyl alcohol as means of hypoglycemic action. Ukraine patent 104448, February 10, 2014.

Tovchiga OV, Shtrygol’ SYu, Stepanova SI. Therapeutic and prevention composition possessing nephroprotecting activity. Ukraine patent 85892, Mar 10, 2009.

Koyro OO. [Role of goutweed (Aegopodium podagraria L.) biologically active substances in nephroprotective, hepatoprotective and hy-pouricemic activity]. Kharkiv: NUPh; 2014.

Tovchiga OV. [The investigation of the goutweed (Aegopodium podagraria L.) diuretic, nephroprotective and hypouricemic action as the basis for the drug development]. Kharkiv: NUPh; 2009.

Ageev VA. [Pharmacognostic study of goutweed (Aegopodium podagraria L.)]. Samara. Novosibirsk State Medical University; 2013.].

Tovchiga OV. [The influence of goutweed(Aegopodium podagraria L.) preparations on the metabolic processes in alloxan-induced diabetic mice]. Pharmacol Med Toxicol. (Farmakolohiia ta likarska toksykolohiia). 2012;5:73–78.

Tovchiga O. Effects of Aegopodium podagraria preparations on the metabolic disorders induced in rats by excess fructose combined with hydrochlorothiazide: the relationship between influence on electrolyte and сarbohydrate metabolism. Int J Biochem Res Rev. 2014;4(4): 80–98.

Tovchiga OV. [Renal effects of goutweed (Aegopodium podagraria L.) preparations in rats with the metabolic disorders induced by fructose and hydrochlorothiazide]. Ukr Biopharm J. 2014; 4 (33): 60–66.

Tovchiga OV. The influence of goutweed (Aegopodium podagraria L.) tincture and metformin on the carbohydrate and lipid metabolism in dexamethasone-treated rats. BMC Complement Altern Med. 2016 Jul 22;16:235. doi: 10.1186/s12906-016-1221-y

Tovchiga OV. Metabolic effects of goutweed (Aegopodium podagraria L.) tincture and metformin in dexamethasone-treated rats. J Dis Med Plants. 2016;2(6):117–126. doi: 10.11648/j.jdmp.20160206.17

Tovchiga OV, Gorbatch TV, Shtrygol’ SYu, Mishchenko MV, Stepanova SI, Taran AV. [The effects of goutweed (Aegopodiumpodagraria L.) preparations and theircombinations with metformin in rats with the disorders of the lipid and carbohydratemetabolism induced by protamine sulphate]. Reviews Clin. Pharm. Drug Ther. 2017;15(2):31–41. [In Russian]. doi: 10.17816/RCF15231-41

Tovchiga OV. Effects of goutweed (Aegopodium podagraria L.) preparations on glycemia in the intact rats and against the background of met-formin. Vìsnik farmacìï. 2017;2(90):54–62.

Tovchiga OV, Shtrygol’ SYu. Metabolic effects of goutweed (Aegopodium podagraria l.) preparations in rats treated with a single dose of ethanol Ukr J Clin Lab Med. 2016;11(4):52–59.

Tovchiga OV. Interaction of Aegopodium podagraria L. (goutweed) with central nervous system depressants. Ukr Biopharm J. 2016;1(42):31–36.

Tovchiga OV, Shtrygol’ SYu, Tovchiga VA. Use of goutweed extract as a preparation with antialcohol effect. Ukraine patent 111644, May 25, 2016.

Tovchiga OV, Gorbatch TV, Shtrygol’ SYu, Stepanova SI. [The influence of gout weed (Aegopodium podagraria L.) preparations on the lipid metabolism in rats treated with a single dose of ethanol]. Pharmacol Med Toxicol. (Farmakolohiia ta likarska toksykolohiia). 2015;4–5(45):87–96..

Tovchiga O, Shtrygol’ S. The influence of Aegopodium podagraria L. extract and tincture on behavioural reactions of random-bred mice. J Chem Pharm Res. 2015;7(7):370–384.

Tovchiga OV, Shtrygol’ SYu. The effect of medicines with goutweed (Aegopodium podagraria L.) on the physical endurance, cognitive functions and the level of depression in animals. Vìsnik farmacìï. 2016;1(85):71–76.

Tovchiga OV. Interaction of Aegopodium podagraria L. (goutweed) with central nervous system depressants. Ukr Biopharm J. 2016;1(42):31–36.

Stefanović O, Radojević I, Vasić S, Čomić L. Antibacterial activity of naturally occurring compounds from selected plants. In: Antimicrobial agents. Ed.Varaprasad Bobbarala. InTech, 2012. doi: 10.5772/33059

Stefanović O, Čomić L, Stanojevic D, Solujic-Sukdolak S. Antibacterial activity of Aegopodium podagraria L. extracts and interaction between extracts and antibiotics. Turk J. Biol. 2009;33:145–150. doi:10.3906/biy-0810-21

Ojala T, Remes S, Haansuu P et al. Antimicrobial activity of some coumarin containing herbal plants growing in Finland J Ethnopharm. 2000;73(1-2):299–305.

Ginsberg HN, Maccallum PR. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: II. Therapeutic management of athero-genic dyslipidemia J Clin Hypertens (Greenwich). 2009;11(9):520–527. doi: 10.1111/j.1559-4572.2009.00060.x.

Bone K, Mills S. Principles and practice of phytotherapy. Modern herbal medicine. Edinburgh;New York: Churchill Livingstone/Elsevier, 2013.

Popova NV, Kazakov GP, Kovalev SV, Stepanova SI. Full-value nutrition as constituental part of self-supporting evolutions and completed approach to health. In: Nutrition innovation aspects of technologies, energy efficient production, storage and marketing. Ed. Prof. V. Evlash, Prof. V. Potapov, Prof. M. Radchenko, Prof. N. Savytska. Kharkiv: Svit knyh, 2016.

Tovchiga OV. [The influence of goutweed (Aegopodium podagraria L.) preparations on the lipid metabolism in rats]. Vestnik VGU. 2017;3.

Koyro OO, Stepanova SI, Shtrygol’ SYu. [Quantitative determination of hydroxycinnamic acids in goutweed raw material]. Journal of Clinical and Laboratory Medicine. 2009;2:12–15.

European Pharmacopoeia. – 4-th ed. – Strasbourg : Council of Europe, 2001.

Tovchiga OV, Shtrygol’ SYu, Stepanova SI, , Yakovleva LV, Samokhin AA. Obtaining, analysis and study of acute toxicity and renal effects of the gout weed (Aegopodium podagraria L.) tincture // Zaporozhye medical journal. 2005;1:121–124.

Kamyshnikov V.S. Manual on Clinical Biochemical Research and Laboratory Diagnostics: MEDpress–inform; 2000

Volochay VI, Kovalуov VM. [The study of amino acids of herb of Galinsoga parviflora Cav and Galinsoga ciliata (Rafin) Blake.]. Zaporozhye medical journal. 2012;3:44–46.

Volochay VI, Chushenko VM, Kovalуov VM, Krasnikova TO. Study of water-soluble polisaccharide complex of the herb of Galinsoga par-viflora. Pharmaceutical review. 2012;1:16–19.

Koyro OO, Stepanova SI, Shtrygol’ SYu. [Mineral composition of goutweed (Aegopodium podagraria L.) leaves and extract]. Medical chemistry. 2009;2:116–119.

Tovchiga OV, Shtrygol’ SYu, Stepanova SI. [Contribution of mineral substances to the mechanism of action of goutweed (Aegopodium podagraria L.) tincture]. Proceeding from Biological features of medicinal and aromatic plants and their role in medicine: International scientific conference dedicated to the 85th anniversary of VILAR. Moscow, 2016. [in Russian].

Prasanna G.S. Pharmacological investigations on the role of Trichilia connaroides (Wight. et Arn.) Bentv. on oxidant status and vascular func-tions in animal models. Bangalore, 2011.

Marzolla V, Armani A, Mammi C et al. Essential role of ICAM-1 in aldosterone-induced atherosclerosis. Int J Cardiol. 2017;232:233–242. doi: 10.1016/j.ijcard.2017.01.013.

Álvarez-Lario B, Macarrón-Vicente J. Uric acid and evolution. Rheumatology (Oxford). 2010; 49(11):2010–2015. doi: 10.1093/rheumatology/keq204.

Kutzing MK, Firestein BL. Altered uric acid levels and disease states. J Pharmacol Exp Ther. 2008;324(1):1–7. doi: 10.1124/jpet.107.129031

DOI: http://dx.doi.org/10.15673/fst.v11i4.726


  • Поки немає зовнішніх посилань.